(RTTNews) - Vivani Medical, Inc. (VANI) Wednesday announced encouraging data from the preclinical study of NPM-139 for chronic weight management in obese and overweight individuals. NPM-139 ...
The Destin Log on MSN7d
Several Destin High weightlifters set personal records at invitationals. One places firstDestin’s Julio Vizcarrondo, competing in the 129-weight class, set a personal record in all three lifts ― 150 on snatch; 215, ...
NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study ...
First for Women on MSN7mon
Eating More Plants Helped This Woman Lose 139 Pounds! How to Enjoy Your Own Plant-Based Weight LossEsther reveals, "Getting healthy can be so simple!" Keep reading to learn about Esther's amazing 139-pound whole-foods ...
Vivani Medical (VANI) announced promising preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight ...
NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in ...
Weight difference versus control group in healthy Sprague-Dawley Rats. % weight change from baseline for NPM-139 (semaglutide) corrected to control (sham implant). Values are mean ± SE.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback